Balancing benefits and risks in the era of biologics

Giovanni Adami*, Kenneth G. Saag, Roland D. Chapurlat, Nuria Guanabens, Glenn Haugeberg, Willem F. Lems, Radmila Matijevic, Nicola Peel, Denis Poddubnyy, Piet Geusens

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Article numberUNSP 1759720X19883973
Number of pages6
JournalTherapeutic Advances in Musculoskeletal Disease
Volume11
DOIs
Publication statusPublished - Oct 2019

Keywords

  • benefit-risk ratio
  • biologics
  • denosumab
  • romosozumab
  • POSTMENOPAUSAL WOMEN
  • RHEUMATOID-ARTHRITIS
  • CERTOLIZUMAB PEGOL
  • ROMOSOZUMAB
  • PREVENTION
  • INFLIXIMAB
  • FRACTURES
  • DENOSUMAB
  • DISEASES
  • SAFETY

Cite this

Adami, G., Saag, K. G., Chapurlat, R. D., Guanabens, N., Haugeberg, G., Lems, W. F., Matijevic, R., Peel, N., Poddubnyy, D., & Geusens, P. (2019). Balancing benefits and risks in the era of biologics. Therapeutic Advances in Musculoskeletal Disease, 11, [UNSP 1759720X19883973]. https://doi.org/10.1177/1759720X19883973